Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company known for its focus on innovative biotech solutions, has announced its support for Unbuzzd Wellness Inc.'s recent $5 million fundraising initiative. This effort, conducted through a Regulation D 506(c) offering in partnership with MZ Digital and Dealmaker, aims to bolster Unbuzzd's direct-to-consumer, retail, and distributor channels. Unbuzzd, the creator of the unbuzzd(TM) beverage designed to accelerate alcohol metabolism and alleviate hangover symptoms, is led by CEO John Duffy, a former Coca-Cola executive, and advised by Gerry David, the ex-CEO of Celsius Holdings. This fundraising move is seen as a strategic step towards an eventual initial public offering (IPO) for Unbuzzd.
Quantum BioPharma Ltd. retains a significant stake in Unbuzzd Wellness Inc., holding 25.71% of Celly Nutrition Corp., the entity behind unbuzzd(TM), as of June 30, 2024. The agreement between Quantum BioPharma and Celly Nutrition includes royalty payments of 7% of sales from unbuzzd(TM) until Quantum BioPharma receives $250 million, after which the royalty decreases to 3% in perpetuity. Additionally, Quantum BioPharma maintains exclusive rights to develop similar products for pharmaceutical and medical applications, underscoring its commitment to addressing alcohol misuse disorders and other metabolic challenges.
This development highlights Quantum BioPharma's strategic approach to fostering innovation within the biotech sector, leveraging its portfolio to support promising ventures like Unbuzzd. The successful raise could significantly impact the beverage and wellness industry, offering consumers innovative solutions to common health concerns while positioning Quantum BioPharma and its affiliates for future growth and market expansion.
